icetana (ASX:ICE) quarterly investor update, July 2021
21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
26Jul
23Jul
icetana (ASX:ICE) quarterly investor update, July 2021
21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
23Jul
icetana (ASX:ICE) quarterly investor update, July 2021
21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
22Jul
icetana (ASX:ICE) quarterly investor update, July 2021
21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
22Jul
icetana (ASX:ICE) quarterly investor update, July 2021
21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
09Jul
ImpediMed (ASX:IPD) – early detection of lymphoedema, July 2021
08 Jul 2021 - ImpediMed Limited (ASX:IPD) CEO and Managing Director Richard Carreon discusses the company's bioimpedance spectroscopy platform SOZO, which is particularly targeted at noninvasive clinical assessment and monitoring of fluid status and tissue composition in the treatment of secondary lymphoedema, heart failure and renal failure.
07Jul
Knosys (ASX:KNO) – Overview of LIBERO acquisition
07 Jul 2021 - Knosys Limited (ASX:KNO Managing Director John Thompson provides an overview of the recent acquisition of LIBERO, a leading library management software business.
05Jul
icetana (ASX:ICE) – AI-driven video analytics surveillance, July 2021
05 Jul 2021 - icetana Limited (ASX:ICE) CEO & Managing Director Matt Macfarlane talks about the company's AI software, which dramatically improves active security monitoring by learning normal movement patterns and highlighting abnormal movement in real time.
04Jul
SUDA Pharmaceuticals (ASX:SUD) acquires invariant natural killer T (iNKT) cell therapy platform, June 2021
01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
01Jul
Nyrada (ASX:NYR) compound combined with statin achieves 65% cholesterol reduction, June 2021
01 Jul 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results from the company's study of its NYX-PCSK9i cholesterol-lowering compound.